Review of thrombotic microangiopathy (TMA), and post-renal transplant TMA

Area of Science:

• Hematology
• Nephrology
• Pathology

Background:

• Thrombotic microangiopathy (TMA) is a rare, severe disorder characterized by microvascular thrombosis, thrombocytopenia, anemia, and organ ischemia.
• TMA encompasses conditions like hemolytic uremic syndrome (HUS) in children and thrombotic thrombocytopenia purpura (TTP) in adults, with endothelial damage and complement dysregulation playing central roles.
• The discovery of ADAMTS 13 has provided crucial insights into TMA pathogenesis.

Purpose of the Study:

• To summarize the key aspects of thrombotic microangiopathy (TMA), including its clinical manifestations, underlying mechanisms, and implications in renal transplantation.
• To highlight the diagnostic and therapeutic challenges associated with TMA, particularly in the context of organ transplantation.

Main Methods:

• Review of existing literature on TMA, HUS, and TTP.
• Analysis of the role of ADAMTS 13 in TMA pathogenesis.
• Examination of TMA as a complication of renal transplantation, including de novo and recurrent forms.

Main Results:

• TMA involves platelet aggregation in small vessels, leading to thrombocytopenia, anemia from erythrocyte fragmentation, and organ damage.
• Endothelial injury and impaired defense against complement activation are critical pathogenic factors.
• TMA is a significant complication post-renal transplantation, with de novo cases often linked to cyclosporine, and recurrence varying based on HUS subtype.

Conclusions:

• TMA is a complex syndrome with diverse etiologies and clinical presentations.
• ADAMTS 13 activity is pivotal in understanding TMA, particularly TTP.
• Management of TMA in renal transplant recipients requires careful consideration of recurrence risk, with contraindication in familial/relapsing HUS.